NCT00934089

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

A Phase 2, Single-masked, Randomized, Crossover Study Of The 24-hour Intraocular Pressure Lowering And Systemic Exposure of Pf-04217329 Alone And In Combination With Latanoprost

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be collected to measure the amount of active metabolite of PF-04217329 in the plasma following dosing.

Conditions

• Glaucoma, Open-Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	PF-04217329	Topical ocular solution, once-daily for 14 days
DRUG	latanoprost vehicle	Topical ocular solution, once-daily for 14 days
DRUG	PF-04217329	Topical ocular solution, once-daily for 14 days
DRUG	latanoprost	Topical ocular solution, once-daily for 14 days

Timeline

• Start date: 2010-01-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2009-07-08
• Last updated: 2021-05-03
• Results posted: 2021-05-03

Locations

8 sites across 1 country: United States